open access
NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
, 2, 1, 1, 3, 1, 2
Affiliations- Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland
- 1st Department of Cardiology, Medical University of Gdansk, Poland
- Division of Quality of Life Research, Department of Psychology, Medical University of Gdansk, Poland
open access
Abstract
Abstract
About this articleTitle
NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
Journal
Issue
Article type
Research Letter
Pages
355-357
Published online
2021-12-01
Page views
5018
Article views/downloads
824
DOI
Pubmed
Bibliographic record
Cardiol J 2022;29(2):355-357.
Authors
Marta Piepiorka-Broniecka
Tomasz A. Michalski
Tomasz Figatowski
Andrzej Wojtowicz
Jaroslaw Jurowiecki
Aleksandra Stanska
Jan Rogowski
Milosz J. Jaguszewski
References (5)- Durães AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D. 2016; 16(2): 149–154.
- Mydin MI, Dimitrakakis G, Younis J, et al. Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate? Interact Cardiovasc Thorac Surg. 2012; 15(1): 109–114.
- Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
- de Souza Lima Bitar Y, Neto MG, Filho JA, et al. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis. Drugs R D. 2019; 19(2): 117–126.
- Guimarães HP, Lopes RD, de Barros E Silva PGM, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020; 383(22): 2117–2126.
